Office Phone: (706) 721-2771
Ravindra Kolhe MD, PhD is the Laboratory Director of the Georgia Esoteric & Molecular Diagnostic Labs in Pathology at GRU. He earned his MD (2001) from Mahatma Gandhi Medical College in India and PhD (2006) from Mississippi State University at Starkville. Dr. Kolhe completed his pathology residency training in the Medical College of Georgia at GRU (2012) where he was also the chief resident. He is a Clinical Assistant Professor and medical director of the cytogenetics laboratory in the Department of Pathology. He is a member of the Clinical Oncology Program in the Cancer Center at GRU. Dr.Kolhe is a reviewer for Laboratory Investigation, the official journal of the United States and Canadian Academy of Pathology.
Dr. Kolhe’s major research interest is in devising and developing new molecular laboratory tests and in identifying newer validated platforms and incorporating them in development of advanced molecular testing for human diseases. This will offer a large variety of molecular markers for diagnosis and predicting therapeutic response in tumors. The long-term goal is to develop molecular (mi-RNA/m-RNA/DNA/protein)-based test panels to aid in the differential diagnosis, prognosis, therapeutic response, and management of various diseases/malignancies.
Ongoing projects in Dr. Kolhe’s laboratory include:
- Identifying miRNA expression in margins and node-negative prostate cancer with biochemical failure.
- Development of dual immunohistochemistry (IHC) and mRNA/miRNA-based chromogenic and fluorescent in situ hybridization on formalin-fixed paraffin-embedded (FFPE) samples.
- Exploring miRNA expression in plasma cell myeloma.
- Development and standardization of automated molecular tests on FFPE lysate, by-passing the target isolation.
- Differential miRNA expression in acute promyelocytic leukemia (APML).
- Molecular characterization of cytogenetically normal acute myeloid leukemia (AML).
- MicroRNA signatures of various aggressive lymphomas.
- Development of laboratory developed tests (LDTs) to integrate the use of IHC, gene-expression, and microarray comparative genomic hybridization (aCGH) technologies to subtype, classify, and predict outcome in diffuse large B cell lymphoma (DLBCL).